Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OS Therapies, Inc.

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Provides Corporate Update
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Announces Closing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Announces Pricing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
From OS Therapies, Inc.
Via Business Wire
Tickers OSTX
OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
From OS Therapies, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.